ESPERION THERAPEUTICS INC. - COMMON STOCK

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

08 May 2025 16:30:00 By Nasdaq GlobeNewswire

Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada

08 May 2025 06:30:00 By Nasdaq GlobeNewswire

Esperion Reports First Quarter 2025 Financial Results

06 May 2025 06:00:00 By Nasdaq GlobeNewswire

Esperion to Participate in The Citizens Life Sciences Conference

25 Apr 2025 08:00:00 By Nasdaq GlobeNewswire

Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

24 Apr 2025 08:00:01 By Nasdaq GlobeNewswire

Esperion to Report First Quarter 2025 Financial Results on May 6

23 Apr 2025 08:00:01 By Nasdaq GlobeNewswire

Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

10 Apr 2025 08:00:00 By Nasdaq GlobeNewswire

Esperion Appoints Robert E. Hoffman to Board of Directors

01 Apr 2025 08:00:00 By Nasdaq GlobeNewswire

Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference

24 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

Esperion Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia

20 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

Esperion Reports Fourth Quarter and Full Year 2024 Financial Results

04 Mar 2025 06:00:00 By Nasdaq GlobeNewswire

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

03 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

18 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

13 Feb 2025 16:30:00 By Nasdaq GlobeNewswire

Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.

09 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference

02 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

18 Dec 2024 07:00:41 By Nasdaq GlobeNewswire

Esperion Announces $210 Million Convertible Debt Financing

13 Dec 2024 06:00:00 By Nasdaq GlobeNewswire

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel

12 Dec 2024 08:00:55 By Nasdaq GlobeNewswire

Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk

02 Dec 2024 08:00:00 By Nasdaq GlobeNewswire